CABALETTA BIO, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CABALETTA BIO, INC. (CABA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- CABALETTA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.50M, a 3.61% decline year-over-year.
- CABALETTA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.26M, a 1.84% increase year-over-year.
- CABALETTA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.82M, a 10.76% increase year-over-year.
- CABALETTA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $5.71M, a 13.80% increase year-over-year.
- CABALETTA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $20.94M, a 7.57% increase from fiscal 2024.
- CABALETTA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $19.46M, a 71.60% increase from fiscal 2023.
- CABALETTA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $11.34M, a 64.46% increase from fiscal 2022.
- CABALETTA BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.90M, a 18.83% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.50M 10-Q · filed 2026-08-13 | $10.76M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $5.26M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $20.94M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $5.82M 10-Q · filed 2025-11-10 | $11.52M derived: sum of 2 quarters · filed 2026-08-13 | $16.68M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $5.71M 10-Q · filed 2026-08-13 | $10.87M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $5.16M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $19.46M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $5.25M 10-Q · filed 2025-11-10 | $10.26M derived: sum of 2 quarters · filed 2025-11-10 | $14.05M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $5.01M 10-Q · filed 2025-11-10 | $8.80M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $3.79M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $11.34M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $3.01M 10-Q · filed 2024-11-14 | $5.81M derived: sum of 2 quarters · filed 2024-11-14 | $8.29M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $2.80M 10-Q · filed 2024-11-14 | $5.28M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $2.48M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $6.90M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $1.73M 10-Q · filed 2023-11-09 | $3.51M derived: sum of 2 quarters · filed 2023-11-09 | $5.32M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.78M 10-Q · filed 2023-11-09 | $3.59M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $1.81M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $5.80M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $1.51M 10-Q · filed 2022-11-10 | $2.89M derived: sum of 2 quarters · filed 2022-11-10 | $4.20M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.39M 10-Q · filed 2022-11-10 | $2.69M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $1.31M 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $4.39M 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $1.13M 10-Q · filed 2021-11-01 | $2.19M derived: sum of 2 quarters · filed 2021-11-01 | $3.07M derived: sum of 3 quarters · filed 2021-11-01 | |
| 2020-06-30 | $1.07M 10-Q · filed 2021-11-01 | $1.94M derived: sum of 2 quarters · filed 2021-11-01 | ||
| 2020-03-31 | $873.00K 10-Q · filed 2021-11-01 | |||
| 2019-12-31 | $2.30M 10-K · filed 2021-03-16 | |||
| 2019-09-30 | $569.00K 10-Q · filed 2020-11-10 | $985.00K derived: sum of 2 quarters · filed 2020-11-10 | $1.48M derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $416.00K 10-Q · filed 2020-11-10 | $912.00K 10-Q · filed 2019-12-05 | ||
| 2019-03-31 | $496.00K 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | $606.00K 10-K · filed 2020-03-30 | |||
| 2018-09-30 | $195.00K 10-Q · filed 2019-12-05 | |||
| 2018-06-30 | $131.00K 10-Q · filed 2019-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |